TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell Midcap Growth Index and returned -4.11% (net) while the index return was -5.22%. The third quarter saw a decline in global equities markets, although they have held up positive year-to-date. In addition, please check the fund’s top five holdings to know its best picks in 2023.
TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted stocks like Repligen Corporation (NASDAQ:RGEN) in the third quarter 2023 investor letter. Headquartered in Waltham, Massachusetts, Repligen Corporation (NASDAQ:RGEN) develops and distributes bioprocessing technologies and systems. On December 15, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $181.21 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 16.43%, and its shares gained 11.57% of their value over the last 52 weeks. Repligen Corporation (NASDAQ:RGEN) has a market capitalization of $10.118 billion.
TimesSquare Capital U.S. Mid Cap Growth Strategy made the following comment about Repligen Corporation (NASDAQ:RGEN) in its Q3 2023 investor letter:
“Our preference within Health Care is for novel therapies to address unmet medical needs, specialized providers, and innovators. Repligen Corporation (NASDAQ:RGEN) is a global sciences company engaged in providing bioprocessing technologies and solutions used to manufacture biologic drugs. They reported mixed second quarter results and lowered forward guidance. Management did however highlight an improving mid and late-stage pipeline as well as expectation for improved orders in the fourth quarter. Investors appear to have looked past the short-term challenges as the stock climbed 13%.”
A laboratory technician researching a sample of cells in a biotechnology laboratory.
Repligen Corporation (NASDAQ:RGEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Repligen Corporation (NASDAQ:RGEN) at the end of third quarter which was 33 in the previous quarter.
We discussed Repligen Corporation (NASDAQ:RGEN) in another article and shared Conestoga Capital Advisors’ views on the company. In addition, please check out our hedge fund investor letters Q3 2023 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
- 12 Extreme Dividend Stocks With Upside Potential
- 30 Largest Cities in the US By Area
- 11 Recent Spin-off Companies That Hedge Funds Are Piling Into
Disclosure: None. This article is originally published at Insider Monkey.
